The ICH E6(R3) Guideline introduces a modernized framework for Good Clinical Practice (GCP), emphasizing flexibility, proportionality, and quality-by-design to better support diverse clinical trial models and evolving technologies.

The International Council for Harmonization (ICH) E6(R3) Guideline, finalized in January 2025, represents a significant evolution in the global standards for Good Clinical Practice (GCP). The Guideline builds upon previous versions by integrating lessons learned from decades of clinical research and addressing the rapid transformation in trial methodologies, digital technologies, and regulatory expectations.

Scope and Structure

The E6(R3) guideline applies to interventional clinical trials of investigational products (IPs). Its flexible, principle-based approach is designed to accommodate academic, industry-sponsored and global trials.

The document is organized into several key sections:

• Introduction
• GCP Principles
• Annex 1: Responsibilities of Research Ethics Boards, investigators, sponsors, and data governance
• Appendices: Investigator’s Brochure, Protocol, Essential Records
• Glossary

Key Concepts

1. Quality-by-Design (QbD)

A cornerstone of E6(R3), QbD encourages sponsors and investigators to proactively identify critical-to-quality (CtQ) factors—elements that directly impact participant safety and data reliability. Rather than focusing on exhaustive documentation or error elimination, the guideline promotes designing trials that are fit-for-purpose, meaning they meet their intended goals without unnecessary complexity by focussing on what is critical.

2. Proportionality

E6(R3) introduces proportionality as a formal GCP principle. This means that trial procedures, oversight, and documentation should be scaled according to the risk, complexity, and context of the study. For example, a low-risk pragmatic trial may not require the same level of monitoring as a high-risk investigational drug study.

3. Fitness-for-Purpose

Closely tied to QbD and proportionality, this concept defines quality as the ability of data and processes to serve their intended purpose. It acknowledges that not all data may need to be verified, as long as the conclusions drawn are valid and reliable.

Principles of GCP

Clinical trials should be designed to protect the rights, safety and well-being of participants and assure the reliability of results. The principles are intended to support efficient approaches to trial design and conduct. They are designed to be flexible and applicable to a broad range of clinical trials.

Stakeholder Responsibilities

Annex 1 describes responsibilities and provides the basis for the appropriate interpretation and application of the principlesand should therefore be appropriately considered. However, various approaches to the provisions in the Annex may be considered provided they are justified and achieve the intended purpose of the application of the principles.

Institutional Review Boards / Independent Ethics Committees (Research Ethics Boards)

• Should ensure ethical conduct and participant protection
• Responsibilities include reviewing protocols, informed consent forms, and safety reports

Investigators

• Accountable for trial conduct, participant safety, and data integrity
• Should focus on CtQ elements and ensure appropriate delegation and oversight
• Emphasis on participant retention and data governance

Sponsors

• Responsible for trial design, monitoring, and overall quality management
• Should apply QbD principles and ensure systems are in place for data protection and compliance
• Encouraged to use risk-based approaches for monitoring and oversight
• Clarification of responsibilities with respect to service providers

Data Governance and Technology

E6(R3) expands guidance on the use of computerized systems, electronic records, and digital tools. It emphasizes:

• Ensuring data integrity and security
• Validating systems used for trial conduct and data capture
• Clear documentation of roles and responsibilities in digital environments

This reflects the growing reliance on electronic data capture (EDC), remote monitoring, and decentralized trial elements.

Essential Records and Documentation

E6(R3) streamlines documentation requirements by focusing on essential records that support trial conduct and regulatory review. It discourages excessive paperwork and promotes clarity on what must be retained, why, and for how long.

Transparency and Inclusivity

The guideline encourages transparency in trial design and conduct, including:

• Clear communication with participants and stakeholders
• Inclusive engagement with diverse populations and trial sites
• Public sharing of trial results and methodologies where appropriate

Implementation and Global Impact

In summary, ICH E6(R3) marks a pivotal shift toward risk-based, participant-centered, and technology-enabled clinical trials. It empowers stakeholders to design and conduct studies that are scientifically sound, ethically robust, and operationally efficient.

Learn more or get involved